Akari Therapeutics Plc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Akari Therapeutics Plc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($6.40M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($1.90M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.90M) | Aug 13, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($3.71M) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($3.71M) | Nov 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($3.71M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.90M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($7.56M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($7.56M) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($5.57M) | Nov 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.57M) | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($5.57M) | Aug 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($2.87M) | Nov 19, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($4.00M) | Aug 19, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($4.00M) | Nov 19, 2024 |
| Q3 | 2024 | Mar 31, 2023 | $1.00M | Nov 19, 2024 |
| Q1 | 2024 | Mar 31, 2023 | $1.00M | May 15, 2024 |
| Q2 | 2024 | Mar 31, 2023 | $1.00M | Aug 19, 2024 |
| Q1 | 2016 | Mar 31, 2016 | ($2.99M) | May 12, 2016 |
| Q3 | 2015 | Sep 30, 2015 | ($48.74M) | Nov 23, 2015 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($7.40M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($3.12M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($3.53M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.93M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($7.45M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.99M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($2.51M) | Nov 19, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($4.62M) | Aug 19, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.59M) | May 15, 2024 |
| Q1 | 2016 | Mar 31, 2016 | ($3.85M) | May 12, 2016 |
| Q3 | 2015 | Sep 30, 2015 | ($23.33M) | Nov 23, 2015 |
| Q2 | 2015 | Jun 30, 2015 | ($1.46M) | Aug 12, 2015 |
| Q1 | 2016 | Mar 31, 2015 | ($1.65M) | May 12, 2016 |
| Q3 | 2015 | Sep 30, 2014 | ($218.0K) | Nov 23, 2015 |
| Q2 | 2015 | Jun 30, 2014 | ($2.33M) | Aug 12, 2015 |
| Q1 | 2015 | Mar 31, 2014 | ($1.88M) | May 12, 2015 |